---
layout: post
title: "Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability"
date: 2026-02-04 21:49:25 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-18653
original_published: 2025-09-25 00:00:00 +0000
significance: 8.00
---

# Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** September 25, 2025 00:00 UTC
**Document Number:** 2025-18653

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft document entitled "Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry." The draft guidance document provides sponsors engaged in the development of regenerative medicine therapies for serious or life-threatening diseases or conditions with FDA's recommendations on the expedited development and review of these therapies. This draft guidance, when finalized, will supersede the final guidance of the same title dated February 2019.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/09/25/2025-18653/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2025-18653

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
